The Role of Frequent Point-of-care Molecular Workplace Surveillance for Miners

Sponsor
University of New Mexico (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT04977050
Collaborator
National Institutes of Health (NIH) (NIH), National Institute of General Medical Sciences (NIGMS) (NIH)
530
1
2
20.3
26.1

Study Details

Study Description

Brief Summary

The long-term goal of the study is to mitigate the spread of the pandemic in miners, a population of high-risk, rural essential workers who are susceptible and vulnerable to COVID-19, partly based on exposure to particulate air pollution, and who are predominantly racial/ethnic minorities in New Mexico (NM) (3, 11). The study objective is to provide proof-of-principle for frequent point-of-care molecular testing as a workplace surveillance tool to monitor and prevent the spread of SARS-CoV-2 infection in this unique population. The central hypothesis is that frequent workplace molecular surveillance is an effective method to reduce SARS-CoV-2 infection and discover novel host risk factors for the virus. The site of molecular surveillance (intervention site) will be a surface coal mine in McKinley County, NM, located just outside the Eastern Agency of the Navajo Nation, comprised of 66% minority miners. This site offers a unique opportunity for a community-based study of SARS-CoV-2 infection in this population. Miners at the intervention site will provide nasal swabs before beginning their work shift on alternate days that will be analyzed with a 'screening' molecular test (12). This test is ideal because it is low cost, simple, portable, point-of-care, rapid, and can be performed by minimally trained professionals in low-infrastructure settings. The control site is a similar coal mine in Campbell County, Wyoming (WY). Both mines, operated by the same company, have similar engineering, administrative, and personal protective measures in place. The rationale for this study is to establish the suitability of longitudinal molecular surveillance to prevent and control SARS-CoV-2 infection in this unique population by completing the following specific aims.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Quidel quickvue antigen test for COVID-19
N/A

Detailed Description

Specific Aim 1: To determine the acceptance rate to frequent point-of-care molecular workplace surveillance among miners.

Hypothesis 1: Miners will have a cumulative acceptance rate of frequent testing at ≥85%, with the added objective of exploring difference in acceptance by miner characteristics.

Specific Aim 2: To determine the ability to detect the presence of SARS-CoV-2 by point-of-care molecular workplace surveillance in a real-world setting of miners.

Hypothesis 2: The sensitivity of the screening test in a real-world study setting is a) comparable to that described by others in controlled settings, and b) positively associated with viral load in upper respiratory specimens (latter measured in nose and nasopharynx using quantitative reverse transcriptase-polymerase chain reaction or RT-PCR).

Specific Aim 3: To determine the effectiveness and implementation costs of frequent point-of-care molecular workplace surveillance on reducing incident infection rates of SARS-CoV-2.

Hypothesis 3A: Frequent point-of-care molecular testing over six months in the intervention mine will result in lower incident seropositivity rates compared to the control mine.

Hypothesis 3B: Frequent point-of-care molecular surveillance in the intervention mine is cost-effective compared to the control mine.

Specific Aim 4: To determine novel predictive host factors associated with incident SARS-CoV-2 infection in miners.

Hypothesis 4: Miners with incident infection demonstrate less frequent use of cloth face-coverings outside the workplace, greater mine dust exposure intensity, presence of dust-related lung disease, and racial/ethnic minority status than those not infected.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
530 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Two groupsTwo groups
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Keeping Rural Minority 'Essential' Workplaces Open Safely During the COVID-19 Pandemic: The Role of Frequent Point-of-care Molecular Workplace Surveillance for Miners (Short Title: The Miners' Pandemic Project)
Actual Study Start Date :
Feb 22, 2021
Anticipated Primary Completion Date :
Nov 1, 2022
Anticipated Study Completion Date :
Nov 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention Site

All miners in the New Mexico intervention mine site who will be administered nasal swabs for antigen testing every other work shift, and serological testing 3 months.

Diagnostic Test: Quidel quickvue antigen test for COVID-19
rapid antigen test on nasal swab specimen for COVID-19

No Intervention: Controled site

All miners in the Wyoming Control mine site who will be administered serological testing 3 months.

Outcome Measures

Primary Outcome Measures

  1. Screening test (molecular) [12 months]

    Rapid antigen test for COVID-19

Secondary Outcome Measures

  1. Diagnostic test (RT-PCR) [12 months]

    Confirmatory COVID-19 test on nasopharyngeal swab

  2. Serologic antibody test [12 months]

    Antibody for COVID-19

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Male or Female Miner employed at intervention mine or the control mine.

  • 18 years of age.

  • Willing and able to provide and sign Informed Consent Form.

  • Willing and able to comply with study procedures.

Exclusion Criteria:
  • Unable or unwilling to provide and sign Informed Consent Form

  • < 18 years of age.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of New Mexico Albuquerque New Mexico United States 87131

Sponsors and Collaborators

  • University of New Mexico
  • National Institutes of Health (NIH)
  • National Institute of General Medical Sciences (NIGMS)

Investigators

  • Principal Investigator: Aksay Sood, MD, University of New Mexico

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
University of New Mexico
ClinicalTrials.gov Identifier:
NCT04977050
Other Study ID Numbers:
  • HRPO 20-680
  • 3U01GM132175-03S1
First Posted:
Jul 26, 2021
Last Update Posted:
Aug 15, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 15, 2022